Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Ipsen S.A. ADR
(OP:
IPSEY
)
29.70
UNCHANGED
Streaming Delayed Price
Updated: 10:34 AM EDT, Aug 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ipsen S.A. ADR
< Previous
1
2
Next >
Week In Review: Foreseen Sells ADC Rights To France's Ipsen In $1 Billion Deal
July 13, 2024
In other news, Sichuan Biokin Pharma has filed for an IPO on the Hong Kong Exchange; more on the Biosecure Act being pushed by US Speaker of the House Johnson.
Via
Talk Markets
Topics
Initial Public Offering
Exposures
Securities Market
FDA Fast-Tracks Ipsen And Genfit's New Liver Disease Treatment, Iqirvo
June 11, 2024
The U.S. FDA has granted accelerated approval for Iqirvo, a novel drug from Ipsen SA and Genfit SA, designed for treating primary biliary cholangitis (PBC). This approval, based on the drug's ability...
Via
Benzinga
Exposures
Product Safety
Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing
November 10, 2023
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Genfit To Buy This Swiss Firm Expanding Its Portfolio in Liver Diseases
September 19, 2022
Via
Benzinga
3 Promising Biotech Stocks Flying Under the Radar
November 08, 2023
Breakthroughs in healthcare are happening everyday, make sure you are keeping up to date on these under the radar biotech stocks.
Via
InvestorPlace
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts
November 01, 2023
Virtual Investor Conference on November 8th and 9th, 2023
From
Virtual Investor Conferences
Via
GlobeNewswire
Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients
August 21, 2023
Roche Holdings AG (OTC: RHHBY), Exelixis Inc (NASDAQ: EXEL), and Ipsen&nbs
Via
Benzinga
Genfit's Miss Is CymaBay Therapeutics' Gain: Analyst Says Rival Data Leaves Room for Seladelpar To Emerge As Best-In-Class
June 30, 2023
Friday, CymaBay Therapeutics Inc's (NASDAQ: CBAY) competitors Genfit SA (NASDAQ: GNFT) and Ipsen SA (OTC:
Via
Benzinga
Ipsen, Genfit's Elafibranor Shows Promise In Primary Biliary Cholangitis Patients
June 30, 2023
Ipsen SA (OTC: IPSEY) and Genfit SA (NASDAQ: GNFT)
Via
Benzinga
What Now After FDA AdComm Rebuke for Intercept Pharmaceutical? Analyst Says Approval Of Intercept's 'OCA In NASH May Never Occur
May 22, 2023
On Friday, FDA's Gastrointestinal Drugs Advisory Committee voted 12 to 2—with two abstentions—that the benefits of Intercept Pharmaceutical Inc's ICPT Ocaliva 25 mg, also known as Obeticholic acid...
Via
Benzinga
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 16th and 17th, 2023
May 09, 2023
From
Virtual Investor Conferences
Via
GlobeNewswire
Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing
May 18, 2023
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U.
January 27, 2023
From
Ipsen
Via
Business Wire
Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde® Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma at ASCO GI
January 20, 2023
From
Ipsen
Via
Business Wire
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 16th and 17th, 2023
May 15, 2023
From
Virtual Investor Conferences
Via
GlobeNewswire
Why These Two Biotech Stocks Blasted Higher This Week
January 13, 2023
There's nothing like a big-premium buyout to send a company's share price to the moon.
Via
The Motley Fool
2 Tiny Nasdaq Stocks Making Major Merger Moves Monday
January 09, 2023
The market is moving higher, and these small companies are helping.
Via
The Motley Fool
France-Based Ipsen Acquires Albireo Pharma Enriching Its Rare Disease Portfolio, Pipeline
January 09, 2023
Via
Benzinga
Ipsen to Acquire Albireo Accelerating Growth in Rare Disease With Treatments for Several Pediatric Liver Diseases
January 09, 2023
From
Ipsen
Via
Business Wire
Ipsen receives Complete Response Letter for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva
December 23, 2022
From
Ipsen
Via
Business Wire
Exelixis' Cabometyx/Tecentriq Combo Misses Overall Survival Goal In Lung Cancer Setting
December 09, 2022
Exelixis Inc (NASDAQ: EXEL) announced that the CONTACT-01 study
Via
Benzinga
Ipsen Provides Update On Phase III CONTACT-01 Trial Evaluating Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Non-small Cell Lung Cancer Previously Treated With Immunotherapy and Chemotherapy
December 08, 2022
From
Ipsen
Via
Business Wire
Why Merrimack Shares Are Surging Over 200% Today?
November 09, 2022
Via
Benzinga
Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
November 09, 2022
From
Ipsen
Via
Business Wire
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
November 01, 2022
October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the...
Via
Benzinga
Ipsen Delivers Strong Sales Growth in the First Nine Months of 2022 and Confirms Its Full-year Guidance
October 27, 2022
From
Ipsen
Via
Business Wire
Ipsen Statement on Updated Timeline for Palovarotene FDA Advisory Committee Meeting
October 25, 2022
From
Ipsen
Via
Business Wire
AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know
October 02, 2022
Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the...
Via
Benzinga
Ipsen Completes Acquisition of Epizyme Expanding Its Portfolio in Oncology
August 12, 2022
From
Ipsen
Via
Business Wire
Ipsen Extends Expiration Date of Tender Offer for Epizyme, Inc. to 11 August 2022
August 05, 2022
From
Ipsen
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.